Beijing Business Daily (Reporter Yao Qian) On March 14th, AstraZeneca announced that it had signed a final agreement to acquire Amolyt Pharma, which has developed innovative therapeutic peptides for rare endocrine and metabolic diseases. AstraZeneca stated that this acquisition will strengthen its Alexion rare disease late stage product line and expand its bone metabolism franchise. According to the transaction terms, AstraZeneca will acquire for a total consideration of up to $1.05 billion, including a prepayment of $800 million.